BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30880552)

  • 21. Systematic Characterization of DNA Methyltransferases Family in Tumor Progression and Antitumor Immunity.
    Huang F; Wu X; Du Q; Lin J; Ma W; Liu J
    Technol Cancer Res Treat; 2024; 23():15330338241260658. PubMed ID: 38847740
    [No Abstract]   [Full Text] [Related]  

  • 22. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adipose tissue inflammation and
    Castellano-Castillo D; Morcillo S; Clemente-Postigo M; Crujeiras AB; Fernandez-García JC; Torres E; Tinahones FJ; Macias-Gonzalez M
    Clin Epigenetics; 2018; 10():60. PubMed ID: 29719581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA methylation markers in colorectal cancer.
    Kim MS; Lee J; Sidransky D
    Cancer Metastasis Rev; 2010 Mar; 29(1):181-206. PubMed ID: 20135198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
    Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
    Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decoupling of DNA methylation and activity of intergenic LINE-1 promoters in colorectal cancer.
    Vafadar-Isfahani N; Parr C; McMillan LE; Sanner J; Yeo Z; Saddington S; Peacock O; Cruickshanks HA; Meehan RR; Lund JN; Tufarelli C
    Epigenetics; 2017 Jun; 12(6):465-475. PubMed ID: 28300471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer.
    de Vogel S; Wouters KA; Gottschalk RW; van Schooten FJ; de Goeij AF; de Bruïne AP; Goldbohm RA; van den Brandt PA; Weijenberg MP; van Engeland M
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3086-96. PubMed ID: 19843671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer.
    Kel A; Boyarskikh U; Stegmaier P; Leskov LS; Sokolov AV; Yevshin I; Mandrik N; Stelmashenko D; Koschmann J; Kel-Margoulis O; Krull M; Martínez-Cardús A; Moran S; Esteller M; Kolpakov F; Filipenko M; Wingender E
    BMC Bioinformatics; 2019 Apr; 20(Suppl 4):119. PubMed ID: 30999858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic silencing of diacylglycerol kinase gamma in colorectal cancer.
    Kai M; Yamamoto E; Sato A; Yamano HO; Niinuma T; Kitajima H; Harada T; Aoki H; Maruyama R; Toyota M; Hatahira T; Nakase H; Sugai T; Yamashita T; Toyota M; Suzuki H
    Mol Carcinog; 2017 Jul; 56(7):1743-1752. PubMed ID: 28218473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptional control of the DNA methyltransferases is altered in aging and neoplastically-transformed human fibroblasts.
    Casillas MA; Lopatina N; Andrews LG; Tollefsbol TO
    Mol Cell Biochem; 2003 Oct; 252(1-2):33-43. PubMed ID: 14577574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma.
    Ogino S; Odze RD; Kawasaki T; Brahmandam M; Kirkner GJ; Laird PW; Loda M; Fuchs CS
    Am J Surg Pathol; 2006 Sep; 30(9):1175-83. PubMed ID: 16931963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and prognosis value of the CIMP status combined with MLH1 or p16
    Saadallah-Kallel A; Abdelmaksoud-Dammak R; Triki M; Charfi S; Khabir A; Sallemi-Boudawara T; Mokdad-Gargouri R
    Med Oncol; 2017 Aug; 34(8):147. PubMed ID: 28730335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines.
    Boot A; Oosting J; van Eendenburg JDH; Kuppen PJK; Morreau H; van Wezel T
    PLoS One; 2017; 12(9):e0184900. PubMed ID: 28931069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel miR-203-DNMT3b-ABCG2 regulatory pathway predisposing colorectal cancer development.
    To KK; Leung WW; Ng SS
    Mol Carcinog; 2017 Feb; 56(2):464-477. PubMed ID: 27253631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.
    Cohen SA; Yu M; Baker K; Redman M; Wu C; Heinzerling TJ; Wirtz RM; Charalambous E; Pentheroudakis G; Kotoula V; Kalogeras KT; Fountzilas G; Grady WM
    Clin Epigenetics; 2017; 9():46. PubMed ID: 28469732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.
    Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M
    Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic Alternations of MicroRNAs and DNA Methylation Contribute to Liver Metastasis of Colorectal Cancer.
    Liu J; Li H; Sun L; Shen S; Zhou Q; Yuan Y; Xing C
    Dig Dis Sci; 2019 Jun; 64(6):1523-1534. PubMed ID: 30604369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence.
    Kocián P; Šedivcová M; Drgáč J; Cerná K; Hoch J; Kodet R; Bartůňková J; Špíšek R; Fialová A
    Hum Immunol; 2011 Nov; 72(11):1022-8. PubMed ID: 21884745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic signatures of familial cancer are characteristic of tumor type and family category.
    Joensuu EI; Abdel-Rahman WM; Ollikainen M; Ruosaari S; Knuutila S; Peltomäki P
    Cancer Res; 2008 Jun; 68(12):4597-605. PubMed ID: 18559504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.